-
2022 EBMT Celebrities Comment on Professor Jiang Erlie: Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia
Time of Update: 2022-04-29
Multivariate analysis of pre-allo-HCT (ALL phenotype, white blood cell count [WBC] at diagnosis, number of complete remissions [CR]), allo-HCT correlation (EBMT score, donor type) and post allo-HCT (plant resistance host disease [GVHD], minimal residual leukemia [MRD]) to assess the prognosis of patients .
-
Guidelines Overview Chinese Guidelines for the Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura (2022 Edition) (2)
Time of Update: 2022-04-29
High-dose intravenous immunoglobulin is less effective than plasma exchange in the treatment of iTPP, and is only suitable for patients with refractory TTP or cases with multiple recurrences .
-
Express is expected to change the first-line treatment mode of lymphoma, and Roche ADC combination is supported by EU CHMP
Time of Update: 2022-04-29
▎WuXi AppTec content team editor Roche (Roche) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of the antibody drug conjugate (ADC) Polivy (polatuzumab vedotin) and the treatment called R-CHP The combination of regimens is used in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL) .
-
Early use of CAR-T may improve treatment outcomes "Nature-Medicine" paper
Time of Update: 2022-04-29
A phase II clinical trial Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial published in Nature Medicine shows that early initiation of axicabtagene ciloleucel (axi-cel) treatment can Activated a complete response in 78% of 37 high-risk large B-cell lymphoma (LBCL) patients .
-
[Fast News] The third live broadcast of the "Precision Medicine" series was successfully concluded. A number of big coffee experts shared the research progress of multiple myeloma and the application of MRD!
Time of Update: 2022-04-29
This live broadcast invited clinical authoritative experts in the field of malignant hematology, blood From a technical point of view, combined with actual clinical practice, Xue Da coffee and the leader of the clinical research and development team introduced the research progress of multiple myeloma and the application of MRD in detail .
-
EBMT 2022 "moving" together, enjoy the CMV academic feast together!
Time of Update: 2022-04-29
A total of 48 true observational studies were included in this meta-analysis, providing additional evidence for the efficacy of letermovir for the prevention of CMV infection and disease in adults with allogeneic HSCT .
-
Professor Feng Ru: PI3K Inhibitors Help FL and MZL "No Chemotherapy", Bringing Survival Benefits to Patients
Time of Update: 2022-04-29
The SAKK 35/10 phase II study showed that the R2 regimen had an overall response rate (ORR) of 81% and a median PFS of 5 years, which was superior to rituximab monotherapy .
-
New thinking on diagnosis and treatment of DLBCL in the first treatment of DLBCL in intensive reading of the first issue of Qunyinghui
Time of Update: 2022-04-29
Intensive literature reading (1) PFS24 may predict long-term survival in newly diagnosed DLBCL patients Professor Zhang Yuanfeng shared an article published by Ann Oncol entitled "Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials (24-month progression-free survival (PFS24) rate and follow-up outcomes of DLBCL patients enrolled in randomized clinical trials)” [1] .
-
Interpretation of the 2021v3 NCCN Guidelines for Systemic Mastocytosis, Avatinib Becomes the First Choice
Time of Update: 2022-04-28
SM is the most common mastocytosis in adults and is characterized by mast cell (MC) infiltration of one or more extracutaneous organs (with or without cutaneous involvement), with variable clinical manifestations and poor patient prognosis, especially patients with advanced SM .
-
The treatment of indolent lymphoma focuses on the intensive reading of the 2nd issue of Qunyinghui.
Time of Update: 2022-04-28
The Efficacy and Safety of Ortuzumab in Relapsed and Refractory FL The GADOLIN study is a global, multicenter, randomized, controlled Phase III clinical study in patients with indolent lymphoma relapsed and refractory to rituximab (FL, MZL, small lymphocytic lymphoma [SLL]) patients were treated with bendamustine monotherapy and octuzumab combined with bendamustine (GB regimen), respectively .
-
A rising rookie with strong potential!
Time of Update: 2022-04-28
Recommended reading: Takeda acquires natural killer γδ T cells and is committed to creating the next generation of "spot" CAR-T innovative productsYimai Meng broke the news In December 2021, Adicet announced its allogeneic CAR-γδ T cells targeting CD20 The therapy ADI-001 in B-cell non-Hodgkin's lymphoma received positive interim data in a dose-escalation Phase 1 clinical trial .
-
Lu Daopei Hospital's new choice for RRMM patients, BCMA CAR-T clinical case sharing
Time of Update: 2022-04-28
>>>>Case Summary This case shows that BCMA CAR-T has a good therapeutic effect for patients with multiple myeloma who are resistant to third-line and above treatment regimens and progress after autologous stem cell transplantation .
-
Ibrutinib combined with rituximab is expected to be an effective first-line treatment option for indolent MCL
Time of Update: 2022-04-28
Table 3: Response 12 months after completion of standard therapy, according to patient molecular subtype (nnMCL or cMCL) and TP53 mutation status Detection of MRD .
-
Nature Commun Shen Shuhong/Liu Yu's team mapped the AML genomic variation in Chinese children and established a precise risk stratification scheme for Chinese children
Time of Update: 2022-04-28
Genomic analysis of the patients' primary tumor samples, detailed description of the genomic driver variation characteristics of Chinese children with acute myeloid leukemia, revealed the unique driver variants and combinations of Chinese children with AML that are different from Western populations, and further based on their prognosis, clinical classification.
-
2022 EBMT Extracorporeal photodissociation therapy - a case study of chronic GVHD based on new experience
Time of Update: 2022-04-28
The patient's current CBC blood count is normal, AST 51 U/L, ALT 55 U/L, AP 400 U/L, GGT 250 U/L, total bilirubin 22 µmol/L, direct bilirubin 12 µmol/L, indirect Bilirubin 10 µmol/L was stable, with slight regression of skin changes associated with chronic GVHD .
-
Induction therapy with ibrutinib and rituximab is safe and effective in young patients with newly diagnosed MCL: the WINDOW-1 study
Time of Update: 2022-04-28
Table 1: Baseline Characteristics of Patients in the WINDOW-1 Study Patient Short-Term Response Patients received a median of 7 cycles of treatment in Part A and 4 cycles in Part B.
-
What should I do if I have relapsed or refractory B-cell lymphoma with CD19 CAR-T?
Time of Update: 2022-04-28
Based on this, the researchers launched a single-center, phase 1/2a prospective study of pembrolizumab for the treatment of patients with relapsed/refractory B-cell lymphoma after CD19 CAR-T cell therapy.
-
Trends in long-term mortality and life expectancy in patients after autologous blood/bone marrow transplantation
Time of Update: 2022-04-28
Transplant protocols have changed significantly over the past 30 years, including: increasing patient age at transplant; increasing selection of autologous BMT for plasma cell disease (PCD); decline in total body irradiation (TBI) as a pre-transplant treatment; selection of peripheral blood Increase in stem cells (PBSC) as a source of stem cells .
-
Multiple myeloma with kidney damage, how to solve the problem?
Time of Update: 2022-04-28
The Canadian Myeloma Collaborative Group’s consensus on the management of MM complications mentioned that the most common cause of MM-related renal insufficiency is light chain cast nephropathy, but it may also be caused by a single Clonal immunoglobulin deposition disease, amyloidosis, cryoglobulinemia, associated with hypercalcemia or hyperuricemia, use of nephrotoxic drugs (eg, NSAIDs, aminoglycosides), use of contrast imaging Differential diagnosis should be done due to drug or (rare) plasma cell infiltration, etc.
-
2022 EBMT Voice of China Prolonged cyclophosphamide infusion time as a stem cell mobilization regimen for NDMM patients is more effective: a retrospective single-center study
Time of Update: 2022-04-28
The First Affiliated Hospital of Sun Yat-Sen University conducted a study to evaluate the efficacy and safety of two different infusion times of Cy + G-CSF for peripheral blood stem cell mobilization in patients with newly diagnosed multiple myeloma (NDMM) .
